Tuesday, June 30, 2015 11:49:42 PM
Gradalis, Inc. Announces Presentation of Data From a Pilot Study of Vigil (TM) Cancer Vaccine in Ewing’s Sarcoma
June 04, 2015 09:15 ET | Source: Gradalis, Inc.
DALLAS, June 04, 2015 (GLOBE NEWSWIRE) -- Gradalis Inc., a clinical-stage biopharmaceutical company, today announced that data from a pilot study for its proprietary personalized cancer vaccine, Vigil™ (previously FANG), in the treatment of patients with Ewing’s sarcoma were presented in Chicago at the 2015 Annual Meeting of the American Society of Clinical Oncology.
Data were presented in a poster session from a Phase 1 trial of 12 metastatic Ewing’s sarcoma patients who were either multiply recurrent (n=11) or had failed frontline treatment within two years (n=1). Patients received Vigil™ in doses of 1x106, 4x106, 1x107 or 2.5x107 cells/intradermal injection/month for at least four months.
Patients were followed for safety and clinical response. Additionally, patients were monitored for tumor-specific immune response using sequential IFN?-ELISPOT (immune activation) assays to assess the functional response of cancer-targeting lymphocytes to unmodified patient-specific tumor samples, starting at baseline (pre-treatment) and sequentially after treatment. Patients were followed for safety and clinical response.
None of the 12 patients (47 doses) developed Grade 2/3/4 drug related toxicity.
For clinical response, one patient achieved a partial tumor response (38% tumor reduction, RECIST 1.1). The estimated Kaplan-Meier median survival of these 12 patients at year 1 was 75%.
For patient immune responsiveness, median product release GM-CSF expression was 1858 pg/106 cells; median knockdown of TGFß1 and TGFß2 was 100% and 99%, respectively. Eight patients have been sequentially assessed for peripheral blood mononuclear cell IFN?-ELISPOT response, all of whom were IFN?-ELISPOT negative at baseline. In all eight, follow up IFN?-ELISPOT at month 1 or month 4 (one patient) post-Vigil™ converted to positive (>10 spots/106 cells and >2x baseline).
“These data demonstrate that Vigil™ was well tolerated, elicited a tumor-specific systemic immune response in all patients, and was associated with favorable 1-year survival,” said John Nemunaitis, M.D., Chief Medical Officer of Gradalis.
Gradalis has initiated a Phase 2b study in refractory Ewing’s sarcoma. The company is also pursuing several other clinical targets for Vigil™ in the Gradalis personalized immunotherapy program including ovarian cancer, and a Phase 1 program in multiple other solid tumors.
About Vigil™
Vigil™ is a proprietary, personalized, immunotherapy platform developed by Gradalis. A patient’s tumor cells are engineered to elicit a systemic T-cell directed immune response when administered to the patient in monthly intradermal injections. By utilizing the patient’s own tumor as the antigen source, Vigil™ is designed to elicit an immune response that is both specifically targeted and broadly relevant to each patient’s unique tumor antigens.
About Gradalis
Gradalis is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of novel proprietary personalized immunotherapies to treat cancer. Gradalis has its own GMP manufacturing facility in Carrolton, Texas. For more information about Gradalis, Inc. please visit www.gradalisinc.com.
- See more at: http://globenewswire.com/news-release/2015/06/04/742225/0/en/Gradalis-Inc-Announces-Presentation-of-Data-From-a-Pilot-Study-of-Vigil-TM-Cancer-Vaccine-in-Ewing-s-Sarcoma.html#sthash.AQ5WAN6L.dpuf
All my posts, comments, and investments are not to be considered investment advice in any way.
Recent BNTC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/29/2024 08:28:27 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/19/2024 08:59:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:18:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 02:22:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/29/2024 08:32:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:13:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:12:19 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 02/26/2024 02:06:56 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:09:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:15:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 01:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:31:00 PM
- Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:03:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:49 PM
- Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/20/2023 08:31:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/20/2023 10:04:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:29:59 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM